First-Line Treatment with Irinotecan and Raltitrexed in Metastatic Colorectal Cancer
Authors:
- Jorge AparicioJAJorge Aparicio
- José M. VicentJVJosé M. Vicent
- Inmaculada MaestuIMInmaculada Maestu
- Carles BoschCBCarles Bosch
- Antonio GalánAGAntonio Galán
- Isabel BusquierIBIsabel Busquier
- Cristina LlorcaCLCristina Llorca
- Salvador GarceráSGSalvador Garcerá
- Juan M. CamposJCJuan M. Campos
- Pedro López-TenderoPLPedro López-Tendero
- Miquel BalcellsMBMiquel Balcells
- 1 April 2005
- journal article
- clinical trial
- Published by S. Karger AG in Oncology
- Vol. 68 (1) , 58-63
Abstract
Objectives: The combination of irinotecan and raltitrexed is safe and active in 5-fluorouracil-refractory, metastatic colorectal cancer (CRC), with the advantage of its convenient three-weekly schedule. The aim of this multicenter phase II study was to assess its efficacy and toxicity in first-line treatment. Methods: Between May 2000 and March 2001, 62 previously untreated patients received irinotecan (350 mg/m2) plus raltitrexed (3 mg/m2), with courses repeated every 21 days. Objective response was assessed every three courses, and treatment maintained until tumor progression or unacceptable toxicity. Results: A total of 331 cycles were administered, with a median of five cycles per patient (range, 1–16). Seventeen patients achieved a partial response and 2 a complete response, for an overall intention-to-treat response rate of 30% (95% confidence interval, 18–44%). The incidence of grade 3–4 toxicity per patient was diarrhea (27%), emesis (13%), anemia (12%), neutropenia (9%), and asthenia (7%). Three patients (5%) died from treatment-related adverse events (diarrhea plus neutropenia). The median potential follow-up is now 37 months. Median survival was 12.2 months, and median time to progression was 6.3 months. Conclusions: The combination of irinotecan plus raltitrexed is an easy comfortable schedule for patients with metastatic CRC, but both efficacy and toxicity results seem suboptimal for first-line treatment.Keywords
This publication has 22 references indexed in Scilit:
- Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trialAnti-Cancer Drugs, 2002
- Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patientsAnnals of Oncology, 2002
- Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)Annals of Oncology, 2002
- Efficacy, tolerability and management of raltitrexed (Tomudex™) monotherapy in patients with advanced colorectal cancerEuropean Journal of Cancer, 2002
- Capecitabine as first-line treatment in colorectal cancerEuropean Journal of Cancer, 2002
- Phase I Clinical and Pharmacogenetic Trial of Irinotecan and Raltitrexed Administered Every 21 Days to Patients With CancerJournal of Clinical Oncology, 2001
- Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinomaCancer, 2001
- Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal CancerJournal of Clinical Oncology, 2000
- Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinomaBritish Journal of Cancer, 2000
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialThe Lancet, 2000